|
|
Blood, 15 May 2004, Vol. 103, No. 10, pp. 3960-3963.
Prepublished online as a Blood First Edition Paper on January 22, 2004; DOI 10.1182/blood-2003-12-4192.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
Angela Dispenzieri,
Robert A. Kyle,
Martha Q. Lacy,
Terry M. Therneau,
Dirk R. Larson,
Matthew F. Plevak,
S. Vincent Rajkumar,
Rafael Fonseca,
Philip R. Greipp,
Thomas E. Witzig,
John A. Lust,
Steven R. Zeldenrust,
Denise S. Snow,
Susan R. Hayman,
Mark R. Litzow,
Dennis A. Gastineau,
Ayalew Tefferi,
David J. Inwards,
Ivana N. Micallef,
Stephen M. Ansell,
Luis F. Porrata,
Michelle A. Elliott, and
Morie A. Gertz
From the Division of Hematology and Internal Medicine and the Division of Biostatistics, Mayo Clinic, Rochester, MN.
Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death. High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy. Selection bias, however, confounds interpretation of these results. We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation. Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and serum alkaline phosphatase. According to design, there was no difference between the groups with respect to sex (57% males), age (median, 53 years), left ventricular ejection fraction (65%), number of patients with peripheral nerve involvement (17%), cardiac interventricular septal wall thickness (12 mm), serum creatinine (1.1 mg/dL [97.24 µmol/L]), and bone marrow plasmacytosis (8%). Sixty-six patients have died (16 cases and 50 controls). For PBSCT and control groups, respectively, the 1-, 2-, and 4-year overall survival rates are 89% and 71%; 81% and 55%; and 71% and 41%. Outside a randomized clinical trial, these results present the strongest data supporting the role of PBSCT in selected patients with AL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
High-dose therapy for amyloidosis: the end of the beginning?
- Jayesh Mehta
Blood 2004 103: 3612-3613.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. Feng, W. D. Edwards, J. K. Oh, K. Chandrasekaran, M. Grogan, M. W. Martinez, I. I. Syed, D. A. Hughes, J. A. Lust, A. S. Jaffe, et al.
Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis
Circulation,
November 20, 2007;
116(21):
2420 - 2426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Haematologica,
October 1, 2007;
92(10):
1351 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, O. Hermine, C. Recher, B. Asli, B. Lioure, B. Royer, et al.
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
N. Engl. J. Med.,
September 13, 2007;
357(11):
1083 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Dember, P. N. Hawkins, B. P.C. Hazenberg, P. D. Gorevic, G. Merlini, I. Butrimiene, A. Livneh, O. Lesnyak, X. Puechal, H. J. Lachmann, et al.
Eprodisate for the Treatment of Renal Disease in AA Amyloidosis
N. Engl. J. Med.,
June 7, 2007;
356(23):
2349 - 2360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. D. Wechalekar, H. J. B. Goodman, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Blood,
January 15, 2007;
109(2):
457 - 464.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Dember
Amyloidosis-Associated Kidney Disease
J. Am. Soc. Nephrol.,
December 1, 2006;
17(12):
3458 - 3471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, M. Skinner, K. Malek, D. G. Wright, K. Quillen, K. Finn, B. Oran, and V. Sanchorawala
Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65
Blood,
December 1, 2006;
108(12):
3945 - 3947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Sanchorawala
Light-Chain (AL) Amyloidosis: Diagnosis and Treatment
Clin. J. Am. Soc. Nephrol.,
November 1, 2006;
1(6):
1331 - 1341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Korbet and M. M. Schwartz
Multiple Myeloma
J. Am. Soc. Nephrol.,
September 1, 2006;
17(9):
2533 - 2545.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al.
Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation
Blood,
March 15, 2006;
107(6):
2578 - 2584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Lindqvist, B.O. Olofsson, C. Backman, O. Suhr, and A. Waldenstrom
Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: A study on patients with familial amyloidotic polyneuropathy
Eur J Echocardiogr,
January 1, 2006;
7(1):
22 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Leung, T. R. Leung, S. S. Cha, A. Dispenzieri, M. Q. Lacy, and M. A. Gertz
Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients
Blood,
November 15, 2005;
106(10):
3353 - 3357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Porrata, M. A. Gertz, M. R. Litzow, M. Q. Lacy, A. Dispenzieri, D. J. Inwards, S. M. Ansell, I. N.M. Micallef, D. A. Gastineau, M. Elliott, et al.
Early Lymphocyte Recovery Predicts Superior Survival after Autologous Hematopoietic Stem Cell Transplantation for Patients with Primary Systemic Amyloidosis
Clin. Cancer Res.,
February 1, 2005;
11(3):
1210 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Dhodapkar, M. A. Hussein, E. Rasmussen, A. Solomon, R. A. Larson, J. J. Crowley, and B. Barlogie
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628
Blood,
December 1, 2004;
104(12):
3520 - 3526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Dispenzieri, A. Moreno-Aspitia, G. A. Suarez, M. Q. Lacy, G. Colon-Otero, A. Tefferi, M. R. Litzow, V. Roy, W. J. Hogan, R. A. Kyle, et al.
Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature
Blood,
November 15, 2004;
104(10):
3400 - 3407.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jaccard, P. Moreau, V. Leblond, and J.-P. Fermand
Best therapy for primary amyloidosis, a not-yet-solved question
Blood,
November 1, 2004;
104(9):
2990 - 2991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. B. Goodman, P. N. Hawkins, A. Dispenzieri, M. A. Gertz, R. A. Kyle, and J. Mehta
The role of PBSCT in treatment of AL amyloidosis is far from settled
Blood,
November 1, 2004;
104(9):
2991 - 2994.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, V. Sanchorawala, K. Malek, D. G. Wright, K. Quillen, K. T. Finn, J. L. Berk, L. M. Dember, R. H. Falk, et al.
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
Blood,
September 15, 2004;
104(6):
1888 - 1893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Gertz, G. Merlini, and S. P. Treon
Amyloidosis and Waldenstrom's Macroglobulinemia
Hematology,
January 1, 2004;
2004(1):
257 - 282.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
